The most common adverse effects in the treated groups were headache, injection-site pain and viral infection. One serious adverse event of generalized urticaria was reported after abatacept ...

KSHB002, a 125 mg/mL pre-filled syringe injection, was evaluated ... Kashiv Biosciences is developing the proposed abatacept biosimilar as both subcutaneous and intravenous formulations.

The biosimilar's safety and immunogenicity profiles were found to be comparable to those of the reference product in the trial.

Kashiv Biosciences, LLC, a global leader in biopharmaceutical innovation, today announced that their abatacept biosimilar candidate, KSHB002, has successfully met the primary endpoints in its Phase 1 ...